Humacyte (HUMA): Director bought ~$66K

~$66K

Approx. value · 50K sh @ $1.32

91K

Holds after · shares reported

Traded

Apr 8, 2025

Filed

Apr 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 7, 2025InsiderDirector purchased ~$20K of HUMA shares in the open market
2. Apr 8, 2025 · this disclosureInsiderDirector purchased ~$66K of HUMA shares in the open market

What came next

1. Apr 8, 2025InsiderDirector purchased ~$7.7K of HUMA shares in the open market
2. Apr 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$42K)
3. Apr 14, 2025InsiderOfficer purchased ~$10K of HUMA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Humacyte

For Humacyte, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HUMA page.

Other recent filings by Kathleen Sebelius, Director

• SEC Form 4 at Humacyte (HUMA)May 20, 2026

The full history of Kathleen Sebelius, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Humacyte

• SEC Form 4Sep 15, 2026
• SEC Form 4Aug 21, 2026
• SEC Form 4Aug 19, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026
• SEC Form 4May 20, 2026

Everything OQRO holds on this company is on its HUMA page.